Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

NCT05162768 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Mitochondrial Myopathies
Mitochondrial Pathology
Mitochondrial DNA Mutation
Mitochondrial Diseases
Mitochondrial DNA Deletion
Mitochondrial DNA Depletion
Mitochondrial Metabolism Defect
Mitochondrial Complex I Deficiency

Interventions

DRUG: Elamipretide
DRUG: Placebo

Sponsor

Stealth BioTherapeutics Inc.